Catriona Waitt

Dolutegravir versus efavirenz in women starting HIV therapy in late pregnancy (DolPHIN-2): an open-label, randomised controlled trial

Kenneth Kintu, Thokozile R. Malaba, Jesca Nakibuka et al. · The Lancet HIV · 2020 · 117 citations · Full text

Treatment And Prevention, Dolutegravir Versus Efavirenz, Reproductive Health +11

Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: A randomised trial (DolPHIN-1 study)

Catriona Waitt, Catherine Orrell, Stephen Walimbwa et al. · PLoS Medicine · 2019 · 105 citations · Full text

Development and validation of a UHPLC-MS/MS method for quantification of the prodrug remdesivir and its metabolite GS-441524: a tool for clinical pharmacokinetics of SARS-CoV-2/COVID-19 and Ebola virus disease

Valeria Avataneo, Amedeo De Nicolò, Jessica Cusato et al. · Journal of Antimicrobial Chemotherapy · 2020 · 104 citations · Full text

Intravenous therapy

Catriona Waitt, Peter Waitt, Munir Pirmohamed · Postgraduate Medical Journal · 2004 · 93 citations · Full text

Good Medical Practice, Intravenous Administration, Central Cannulae +9

72 weeks post-partum follow-up of dolutegravir versus efavirenz initiated in late pregnancy (DolPHIN-2): an open-label, randomised controlled study

Thokozile R. Malaba, Irene Nakatudde, Kenneth Kintu et al. · The Lancet HIV · 2022 · 50 citations · Full text